



Edgar Filing: BIO-PATH HOLDINGS INC - Form 8-K

2626 South Loop, Suite 180, Houston, Texas 77054  
(Address of principal executive offices) (Zip Code)

832-971-6616

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On May 29, 2012, Bio-Path Holdings, Inc. issued a press release titled “Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia.”

A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit<br>Number | Description                      |
|-------------------|----------------------------------|
| 99.1              | Press Release dated May 29, 2012 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIO-PATH HOLDINGS, Inc.**

Dated: May 29, 2012 By: /s/ Peter H. Nielsen  
Peter H. Nielsen

President and Chief Executive Officer

**EXHIBIT INDEX**

| Exhibit<br>Number | Description                      |
|-------------------|----------------------------------|
| 99.1              | Press Release dated May 29, 2012 |